Advanced Search

    Technical Analysis for PTCT - PTC Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 42.90 -2.78% -1.23
    PTCT closed up 1.43 percent on Friday, June 2, 2023, on 78 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical PTCT trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction -2.78%
    Narrow Range Bar Range Contraction -2.78%
    Doji - Bearish? Reversal -2.78%
    Wide Bands Range Expansion -2.78%
    Up 3 Days in a Row Strength -2.78%
    Oversold Stochastic Weakness -2.78%
    Slingshot Bearish Bearish Swing Setup -1.39%
    Lower Bollinger Band Walk Weakness -1.39%
    Wide Bands Range Expansion -1.39%
    Oversold Stochastic Weakness -1.39%
    Older End-of-Day Signals for PTCT ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    60 Minute Opening Range Breakdown about 2 hours ago
    Down 3% about 3 hours ago
    Fell Below Previous Day's Low about 4 hours ago
    Down 2 % about 4 hours ago
    Down 1% about 4 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    PTCT Chart by TradingView
    Basic chart:

    Profile

    PTC Therapeutics, Inc. Description

    PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules. The company has strategic alliances with AstraZeneca; Celgene Corporation; Cystic Fibrosis Foundation; Genzyme Corporation; Gilead; Muscular Dystrophy Association; Merck & Co., Inc.; Parent Project Muscular Dystrophy; Pfizer Inc.; Roche; Spinal Muscular Atrophy Foundation; and Wellcome Trust. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Infectious Diseases Neurological Disorders Gene Expression Dystrophy Cystic Fibrosis Muscular Dystrophy Neurodegenerative Disorders Transcription Spinal Muscular Atrophy Genzyme Neuromuscular Disorders

    Is PTCT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 2 PTC Therapeutics to Participate at Upcoming Investor Conferences
    May 31 PTC Therapeutics, Inc. (NASDAQ:PTCT) Might Not Be As Mispriced As It Looks After Plunging 25%
    May 25 PTC Therapeutics: Rare Disease Specialist's Stock In Danger Of Slipping Further
    May 25 Biotech Stock Roundup: IRWD Announces Buyout, ICPT, SRPT & PTCT Fall on Updates
    May 24 Reata adds 21% as PTC’s Friedreich's ataxia drug fails Phase 3 trial
    May 24 PTC Therapeutics' (PTCT) Rare Disease Drug Fails in Study
    May 24 PTC Therapeutics Stock Tumbles: Company Stops Preclinical Gene Therapy Programs After Failed Friedreich's Ataxia Study
    May 24 Why Inovio Pharmaceuticals Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
    May 24 PTC abandons preclinical gene therapy programs, cuts staff; CFO departs
    May 23 Dow Jones Futures: Market Rally Retreats Amid Debt-Ceiling Drama; Nvidia Earnings Due
    See more PTCT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 59.75
    52 Week Low 25.04
    Average Volume 873,603
    200-Day Moving Average 46.64
    50-Day Moving Average 51.08
    20-Day Moving Average 51.96
    10-Day Moving Average 47.97
    Average True Range 2.69
    RSI (14) 35.06
    ADX 33.06
    +DI 17.40
    -DI 37.17
    Chandelier Exit (Long, 3 ATRs) 51.68
    Chandelier Exit (Short, 3 ATRs) 49.03
    Upper Bollinger Bands 64.96
    Lower Bollinger Band 38.97
    Percent B (%b) 0.2
    BandWidth 50.02
    MACD Line -2.66
    MACD Signal Line -1.06
    MACD Histogram -1.5922
    Fundamentals Value
    Market Cap 3.01 Billion
    Num Shares 68.2 Million
    EPS -4.10
    Price-to-Earnings (P/E) Ratio -10.76
    Price-to-Sales 11.48
    Price-to-Book 8.55
    PEG Ratio 0.81
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 46.13
    Resistance 3 (R3) 46.00 45.20 45.80
    Resistance 2 (R2) 45.20 44.69 45.27 45.68
    Resistance 1 (R1) 44.66 44.37 44.93 44.79 45.57
    Pivot Point 43.86 43.86 44.00 43.93 43.86
    Support 1 (S1) 43.32 43.35 43.59 43.45 42.67
    Support 2 (S2) 42.52 43.03 42.59 42.56
    Support 3 (S3) 41.98 42.52 42.45
    Support 4 (S4) 42.11